CLINICAL TRIALS PROFILE FOR EPINEPHRINE (AUTOINJECTOR)

All Clinical Trials for EPINEPHRINE (AUTOINJECTOR)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03964051 ↗	Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).	Active, not recruiting	Miltenyi Biomedicine GmbH	Phase 4	2019-07-01	Anaphylaxis elicited by accidental intake of the offending food constitutes a major health risk to the food allergic patient. Current advice for the food allergic patient is to avoid the offending food allergen and to carry an epinephrine autoinjector. However, novel treatments altering the clinical reactivity to the offending food thereby diminishing the risk of anaphylaxis are much needed. A correlation between the level of specific IgE in serum towards the offending food and the clinical sensitivity of the patient has been suggested. The clinical threshold for a food allergic reaction to occur is therefore hypothesized to increase by reducing the level of specific IgE to the relevant food allergen. Therapy with Omalizumab has proven efficacious in lowering the level of IgE in serum but a high pre-treatment level of total IgE in serum potentially hampers the efficacy in a number of patients, as seen especially in patients with concomitant atopic dermatitis. The aim of this study is to investigate if the combination of initial IgE specific immunoadsorption combined with subsequent treatment with Omalizumab will increase the clinical threshold to the culprit food and thus prevent medical emergencies (anaphylaxis) in patients with severe food allergy.
NCT03964051 ↗	Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).	Active, not recruiting	Miltenyi Biotec GmbH	Phase 4	2019-07-01	Anaphylaxis elicited by accidental intake of the offending food constitutes a major health risk to the food allergic patient. Current advice for the food allergic patient is to avoid the offending food allergen and to carry an epinephrine autoinjector. However, novel treatments altering the clinical reactivity to the offending food thereby diminishing the risk of anaphylaxis are much needed. A correlation between the level of specific IgE in serum towards the offending food and the clinical sensitivity of the patient has been suggested. The clinical threshold for a food allergic reaction to occur is therefore hypothesized to increase by reducing the level of specific IgE to the relevant food allergen. Therapy with Omalizumab has proven efficacious in lowering the level of IgE in serum but a high pre-treatment level of total IgE in serum potentially hampers the efficacy in a number of patients, as seen especially in patients with concomitant atopic dermatitis. The aim of this study is to investigate if the combination of initial IgE specific immunoadsorption combined with subsequent treatment with Omalizumab will increase the clinical threshold to the culprit food and thus prevent medical emergencies (anaphylaxis) in patients with severe food allergy.
NCT03964051 ↗	Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).	Active, not recruiting	Carsten Bindslev-Jensen	Phase 4	2019-07-01	Anaphylaxis elicited by accidental intake of the offending food constitutes a major health risk to the food allergic patient. Current advice for the food allergic patient is to avoid the offending food allergen and to carry an epinephrine autoinjector. However, novel treatments altering the clinical reactivity to the offending food thereby diminishing the risk of anaphylaxis are much needed. A correlation between the level of specific IgE in serum towards the offending food and the clinical sensitivity of the patient has been suggested. The clinical threshold for a food allergic reaction to occur is therefore hypothesized to increase by reducing the level of specific IgE to the relevant food allergen. Therapy with Omalizumab has proven efficacious in lowering the level of IgE in serum but a high pre-treatment level of total IgE in serum potentially hampers the efficacy in a number of patients, as seen especially in patients with concomitant atopic dermatitis. The aim of this study is to investigate if the combination of initial IgE specific immunoadsorption combined with subsequent treatment with Omalizumab will increase the clinical threshold to the culprit food and thus prevent medical emergencies (anaphylaxis) in patients with severe food allergy.
NCT05166343 ↗	POHCA Resuscitation: Evaluation of IM Epinephrine	Not yet recruiting	Lawson Health Research Institute	Phase 2/Phase 3	2022-01-01	This is a pragmatic, two-arm, open-label, prospective stepped-wedge cluster randomized control trial (SW-CRCT) looking to evaluate early intramuscular (IM) epinephrine in the management of pediatric out-of-hospital cardiac arrest (POHCA).

Clinical Trial Conditions for EPINEPHRINE (AUTOINJECTOR)

Condition Name

Condition Name for EPINEPHRINE (AUTOINJECTOR)
Intervention	Trials
Allergy	1
Anaphylaxis	1
Food Allergy	1
Pediatric Out-of-Hospital Cardiac Arrest	1

Condition MeSH

Condition MeSH for EPINEPHRINE (AUTOINJECTOR)
Intervention	Trials
Anaphylaxis	2
Hypersensitivity	1
Out-of-Hospital Cardiac Arrest	1
Heart Arrest	1

Clinical Trial Locations for EPINEPHRINE (AUTOINJECTOR)

Trials by Country

Trials by Country for EPINEPHRINE (AUTOINJECTOR)
Location	Trials
Canada	2
Denmark	1

Clinical Trial Progress for EPINEPHRINE (AUTOINJECTOR)

Clinical Trial Phase

Clinical Trial Phase for EPINEPHRINE (AUTOINJECTOR)
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for EPINEPHRINE (AUTOINJECTOR)
Clinical Trial Phase	Trials
Active, not recruiting	1
ENROLLING_BY_INVITATION	1
Not yet recruiting	1

Clinical Trial Sponsors for EPINEPHRINE (AUTOINJECTOR)

Sponsor Name

Sponsor Name for EPINEPHRINE (AUTOINJECTOR)
Sponsor	Trials
Lawson Health Research Institute	1
Nasus Pharma	1
Miltenyi Biomedicine GmbH	1

Sponsor Type

Sponsor Type for EPINEPHRINE (AUTOINJECTOR)
Sponsor	Trials
Industry	3
Other	2

Clinical Trials Update and Market Outlook for Epinephrine (Autoinjector)

Last updated: April 26, 2026

What is the current clinical-trials landscape for epinephrine autoinjectors?

Epinephrine autoinjectors are largely built around mature, established clinical evidence with ongoing work focused on label refinements, device usability, cross-brand bridging, and specific populations (pediatrics and education/training outcomes). As of the most recent public reporting, the core development programs for autoinjectors remain centered on:

• Device design and usability (activation force, needle visibility, misfire/failed deployment characterization, and injection time).
• Comparative pharmacokinetics (PK)/pharmacodynamics and bridging between formulations or devices rather than novel efficacy trials.
• Human factors and real-world administration training endpoints (time-to-injection, correct activation, and usability under stress).

Trial pattern: Many programs for autoinjectors are structured as randomized crossover or bridging studies in healthy volunteers or controlled settings, with secondary endpoints on device performance, injection success, and usability. Post-market studies and registry-style data collections also inform label language around indications and administration steps.

Which clinical-trials signals matter commercially?

For autoinjectors, commercial risk typically concentrates in four measurable areas that trials and post-market studies track:

1. Failed-deployment and misfire rates (device reliability under realistic handling).
2. Injection delivery characteristics (delivered dose distribution and needle placement success).
3. Usability outcomes (time-to-activation, error rates by user group).
4. Pediatric performance (appropriateness by weight band and administration technique).

These signals directly impact:

• Competitive positioning versus other brands.
• Market access conversations where reliability and administration confidence drive preference.
• Liability and pharmacovigilance posture, which can shape payer and institutional buying decisions.

How does the competitive market structure look?

The epinephrine autoinjector market is consolidated around major brands with extensive historical penetration and repeated re-supply cycles driven by:

• Anaphylaxis prevalence in target settings (schools, restaurants, healthcare facilities).
• Stocking mandates and emergency preparedness policies.
• School and public-access adoption programs.
• Household coverage where patient education and ease of use are purchase drivers.

Key commercial dynamics

• Brand switching is constrained by patient familiarity, clinician prescribing habits, and device usability learning curves.
• Tender and institutional purchasing place heavy weight on reliability, availability, and total cost (including training and refill cadence).
• Dose positioning by weight (adult vs pediatric units) is central to product lineup and procurement decisions.

What does the market data imply for forecast direction?

Near-term growth is supported by consistent demand rather than rapid therapeutic innovation. The main drivers that shape projections are:

• Expansion of public-access and school stocking initiatives in multiple regions.
• Ongoing uptake of autoinjectors in community settings (workplaces, travel, sports).
• Lifecycle activity that refreshes patient access and device adoption (rebranding, label updates, packaging changes).

Counterweights include:

• Policy and reimbursement friction (formularies, procurement rules).
• Supply and manufacturing constraints that can delay shipments and compress sales during shortage windows.
• Competitive price pressure during tenders and budget cycles.

Market projection framework (base case)

Because the category is mature and most activity is device-focused, projections typically track:

1. Unit demand growth from adoption and stocking policies.
2. Share shifts driven by device reliability reputation, availability, and payer preferences.
3. Price impacts linked to tender outcomes and reimbursement tier changes.

In practical forecasting terms for investors and R&D stakeholders, the highest-leverage assumptions are:

• Uptake rate of public access and school use by geography.
• Share stability vs. switching based on device performance and user experience.
• Supply reliability and whether manufacturing expansions keep pace with demand.

Where are the major commercial risks and watch items?

Device reliability and safety monitoring

Even when efficacy is established, commercial outcomes can swing with:

• Reports of misfires or under-delivery patterns for specific lots.
• Corrective actions tied to device performance.
• Labeling changes based on human factors or usability findings.

Competitive pricing and procurement cycles

Autoinjectors face:

• High sensitivity to tender pricing and volume discounts.
• Procurement seasonality (school-year stocking, hospital budget cycles).
• Competitive substitution among brands when supply and price align.

Regulatory and label alignment

Programs that update instructions for use, administration steps, or training materials can improve uptake. Conversely, misalignment between device design and training content can degrade real-world adoption.

Clinical development priorities likely to shape next-cycle competition

Autoinjector pipelines typically cluster around:

• Dose-appropriate devices for pediatrics with improved usability.
• Reliability improvements that reduce misfire probability and improve injection success.
• Human factors work that tightens the link between device operation and intended use in real settings.
• Bridging strategies that speed commercialization without re-running core efficacy trials.

These themes drive both patent strategy and investment decisions because they influence:

• How quickly new entrants can gain share.
• How effectively existing players can defend against substitution.

Epinephrine autoinjectors: what to monitor in upcoming readouts

For business and R&D valuation, the most decision-grade trial and post-market readouts are:

• Primary endpoints: successful activation, injection completion, and delivered dose characteristics.
• Secondary endpoints: time-to-injection and error rates under realistic constraints (low visibility, stress, caregiver handling).
• Subgroup reporting: pediatric weight bands and caregiver types.
• Comparative studies: head-to-head device performance or cross-device bridging.

Key Takeaways

• Epinephrine autoinjector development is concentrated in device performance, human factors, and bridging, not novel efficacy discovery.
• The clinical signal that drives commercial outcomes is reliability and correct administration performance in real-world or simulated use.
• Market growth is driven primarily by public access and institutional stocking, with competitive share influenced by availability, procurement pricing, and user experience.
• The highest-impact forecast variables are adoption (unit demand), share stability/switching, and supply reliability, with pricing and tender cycles as the main counterweights.

FAQs

1) Do epinephrine autoinjectors still run major efficacy trials?

Most category activity focuses on bridging, usability, and device performance rather than establishing new efficacy from scratch, given the mature evidence base.

2) What clinical endpoints most affect payer and institutional acceptance?

The highest commercial weight typically sits on misfire/failure rates, injection success, and time-to-activation and error rates from human factors or simulated-use studies.

3) How do public-access initiatives change the market?

They increase baseline unit demand by shifting epinephrine autoinjector use from household-only ownership to schools and community settings, creating more predictable replenishment cycles.

4) What is the biggest commercial threat to autoinjector brands?

Unfavorable device reliability signals, supply interruptions, and adverse procurement pricing during tender cycles.

5) What pipeline areas are most likely to shift competitive dynamics?

Programs that reduce activation difficulty, improve injection success, and strengthen caregiver and pediatric usability are the most likely to support share gains.

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. (n.d.). Epinephrine autoinjector search results. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. (n.d.). Drug Trials Snapshots and related regulatory materials for epinephrine products. https://www.fda.gov/
[3] World Health Organization. (n.d.). Anaphylaxis and epinephrine use guidance and related resources. https://www.who.int/
[4] European Medicines Agency. (n.d.). Scientific guidance and assessment materials for emergency medicines and device-related studies. https://www.ema.europa.eu/
[5] Centers for Disease Control and Prevention. (n.d.). Anaphylaxis and epinephrine use resources. https://www.cdc.gov/